Skip to content

DMT: all studies

Page 87 of 160: studies 861 to 870 of 1,593, newest first. Back to the DMT overview

Research

Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons

Journal of Neurochemistry February 28, 2025 Aneta Petrušková, Debarpan Guhathakurta, Enes Yağız Akdaş et al. 8 citations

ABSTRACT The serotonergic psychedelics psilocybin, LSD and DMT hold great promise for the development of new treatments for psychiatric conditions such as major depressive disorder, addiction and end‐of‐life anxiety. Previous studies in both animals and humans have confirmed the effects of these drugs on neuronal activity and plasticity. However, the understanding of the mechanisms of action of...

Hemp proteins conjugated with green tea polyphenol extract form de novo plant-sourced emulsifiers suitable for nanodelivery systems bearing lipophilic psychopharmaceuticals

ChemRxiv February 27, 2025 William Charles Hosie, Mary Augustina Egbuta, Kasra Razmkhah et al. preprint

Nanoformulation is often used to improve the solubility and uptake of bioactives; however, it also protects sensitive bioactives from chemical decomposition. We report a class of biocompatible emulsifiers created by conjugating hemp protein with green tea polyphenols. A simple pH-assisted coupling protocol was employed to synthesize covalent and non-covalent conjugates, which were then used to...

DOI: 10.26434/chemrxiv-2025-pjfn9 (opens in new tab) Full text (opens in new tab) Polyphenol Green tea Conjugated system Traditional medicine

Psychedelics are Bringing a new wind to the Pharmacopoeia

Neuroscience and Neurological Surgery February 27, 2025 Michel Bourin

Hallucinogenic substances such as psilocybin, LSD or ecstasy are now the subject of several hundred clinical trials around the world to test their ability to restore our mental health. Psilocybin (active ingredient in hallucinogenic mushrooms), LSD (derived from compounds from ergot), dimethyltryptamine (or DMT, part of the composition of ayahuasca), mescaline (derived from peyote), but also...

Psychedelics and Suicide-Related Outcomes: A Systematic Review

Journal of Clinical Medicine February 20, 2025 Shakila Meshkat, Taha Malik, Jennifer Swainson et al. 3 citations

Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscores the need for alternatives. Psychedelic therapies may rapidly reduce suicide risk. This systematic review evaluates impact of psychedelic therapies on suicide-related outcomes. Methods: A systematic search of MEDLINE, Embase, PsycINFO, and...

Psychosis in a Military Veteran in the Context of Hallucinogen Use: A Case Report.

Cureus February 19, 2025 Paria Parhami, Sydney E Moriarty, Jay Parikh et al.

N, N-dimethyltryptamine (DMT) is a potent hallucinogenic compound with increasing recreational use despite limited safety data. While DMT use has been linked to psychosis, delusional parasitosis as a specific manifestation remains unreported. We present a novel case of a 60-year-old female veteran with chronic post-traumatic stress disorder (PTSD), a history of major depressive disorder, past...

DOI: 10.7759/cureus.79308 (opens in new tab) Full text (opens in new tab) Substance-induced psychosis Drug-induced psychosis Hallucinogen-induced psychosis Substance-related psychosis +21

Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.

ACS Medicinal Chemistry Letters February 13, 2025 Robert B. Kargbo

Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors...

Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression

Nature Communications February 12, 2025 Farid Aboharb, Pasha A. Davoudian, Ling-Xiao Shao et al. 19 citations

Psilocybin, ketamine, and MDMA are psychoactive compounds that exert behavioral effects with distinguishable but also overlapping features. The growing interest in using these compounds as therapeutics necessitates preclinical assays that can accurately screen psychedelics and related analogs. We posit that a promising approach may be to measure drug action on markers of neural plasticity in...

Can psychedelic use benefit meditation practice? Examining individual, psychedelic, and meditation-related factors.

PLoS One February 12, 2025 Zishan Jiwani, Simon B. Goldberg, Jack Stroud et al. 3 citations

INTRODUCTION: Meditation practice and psychedelic use have attracted increasing attention in the public sphere and scientific research. Both methods induce non-ordinary states of consciousness that may have significant therapeutic benefits. Thus, there is growing scientific interest in potential synergies between psychedelic use and meditation practice with some research suggesting that...

Plant-derived compounds and neurodegenerative diseases: Different mechanisms of action with therapeutic potential.

Neuroscience February 6, 2025 Carolina Echeverry, Mariana Pazos, Maximiliano Torres-Pérez et al. 9 citations

Neurodegenerative diseases are a group of disorders characterized by progressive degeneration of discrete groups of neurons causing severe disability. The main risk factor is age, hence their incidence is rapidly increasing worldwide due to the rise in life expectancy. Although the causes of the disease are not identified in about 90% of the cases, in the last decades there has been great...

Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V February 1, 2025 Octavio E Fandiño, Aaron R J Hutton, Chunyang Zhang et al. 4 citations

Throughout history, psychedelic compounds have been used for religious, spiritual and recreational purposes. A plethora of studies have reported the use of psychedelic compounds in the treatment of various conditions, such as alcoholism, addictions, depressive state to borderline schizophrenia, personality disorder, among other mental disorders. Psychedelic microdosing, a common technique in...